Professor Dr. Anna Sureda Balari, Head of the Haematology Department at the Catalan Institute of Oncology (ICO) in Barcelona, is the President of EBMT, a scientific and medical society bringing together a community of healthcare professionals, involved in clinical haematopoietic cell transplantation and cellular therapy.Together with Tuula Rintala and Natacha Bolaños, she represents the EBMT community, which - in addition to healthcare professionals - closely partners with patients and donors through its Patient Advocacy Committee.EBMT is not only a professional network but also the host of the official European Registry for both haematopoietic cell transplantation and CAR T-cell therapy, generating real-world evidence that directly informs clinical practice and policy.Within the EASYGEN Consortium, EBMT plays a central role in work package 2 (process management and co-creation) and work package 9 (dissemination, communication, and patient advocacy). The society contributes its deep scientific expertise and leverages its Registry data and clinical network to study patient quality of life, treatment access, and the real-world performance of next-generation CAR-T therapies.By positioning scientific progress within a truly patient-centred framework, EBMT ensures that innovation in EASYGEN remains clinically meaningful, responsible, and aligned with patient and healthcare-system needs — bringing advanced cell and gene therapies closer to those who need them most.Collaboration. Innovation. Access. That’s what EASYGEN - and partners like - EBMT stand for.#CART #PatientCare #PatientAdvocacy #QualityOfLife #EBMT